Genoxal 1.000 mg polvo para solución inyectable y para perfusión

DRUG5 trials

Sponsors

Cellectis, Fundacio Institut D Investigacio Biomedica De Bellvitge IDIBELL, Vall D Hebron Institute Of Oncology, Cabaletta Bio Inc., Fundacion De Investigacion Biomedica De Salamanca

Conditions

Active Systemic Lupus Erythematosus;Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by autoantibody production and abnormal B cell function. SLE presents with fluctuating severity and may cause tissue damage in a variety of organs over time. Lupus nephritis (LN) is a common severe manifestation of SLEAdvanced selected solid tumors: melanomaAdvanced solid tumorsRelapsed or refractory B-cell Non-Hodgkin lymphomaRelapsed or refractory B-cell lymphomanon-small cell lung cancer (NSCLC) and cervical cancer.which can lead to significant morbidity and mortality.

Phase 1

Open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART20x22 in subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

RecruitingCTIS2022-501607-27-00

CellectisRelapsed or refractory B-cell Non-Hodgkin lymphoma

Start: 2026-01-06Target: 48Updated: 2026-01-08

A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Systemic Lupus Erythematosus

RecruitingCTIS2023-507613-10-01

Cabaletta Bio Inc.Active Systemic Lupus Erythematosus;Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by autoantibody production and abnormal B cell function. SLE presents with fluctuating severity and may cause tissue damage in a variety of organs over time. Lupus nephritis (LN) is a common severe manifestation of SLE, which can lead to significant morbidity and mortality.

Start: 2025-03-31Target: 6Updated: 2026-01-26

Phase I/IIa multicentre phase I/IIa study of infusion of autologous peripheral blood T lymphocytes expanded and genetically modified using Sleeping Beauty family transposons to express a chimeric antigenic receptor with anti-CD19 specificity conjugated to the 4-1BB co-stimulatory and signal-transduction region CD3z and huEGFRt (TranspoCART19) in patients with relapsed or refractory B-cell lymphoma.

RecruitingCTIS2024-514544-90-00

Fundacion De Investigacion Biomedica De SalamancaRelapsed or refractory B-cell lymphoma

Start: 2024-03-11Target: 27Updated: 2025-12-02

Phase 2

A phase 2, Multicenter Study of TILs Treatment in Advanced Tumors with Alterations in the SWI/SNF Complex: the TILTS Study

RecruitingCTIS2023-504632-17-00

Fundacio Institut D Investigacio Biomedica De Bellvitge IDIBELLAdvanced solid tumors

Start: 2024-08-14Target: 11Updated: 2025-08-19

Phase II randomized study evaluating a Pragmatic approach to Adoptive Cell Therapy (ACT) using an IL2 analog (ANV419) vs High dose IL2 after Tumor Infiltrating Lymphocytes (TIL) Therapy in patients with melanoma, NSCLC and cervical cancer. The PragmaTIL

RecruitingCTIS2023-506400-99-00

Vall D Hebron Institute Of OncologyAdvanced selected solid tumors: melanoma, non-small cell lung cancer (NSCLC) and cervical cancer.

Start: 2025-01-15Target: 24Updated: 2025-12-02

Related Papers

Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS study

Future Oncology2024-08-12

A phase 2, multicenter study of TILs treatment in advanced tumors with alterations in the SWI/SNF complex: The TILTS study.

Journal of Clinical Oncology2024-06-01